Inflarx N.V. (IFRX)
NASDAQ:IFRX
Want to see IFRX full AI Analyst Report?
IFRX Stock Chart & Stats
$1.59
-$0.16(-6.27%)
At close: 4:00 PM EST
$1.59
-$0.16(-6.27%)
Day’s Range― - ―
52-Week Range$0.74 - $2.95
Previous CloseN/A
Volume66.97K
Average Volume (3M)2.60M
Market Cap
$319.63M
Enterprise Value$134.48M
Total Cash (Recent Filing)$39.84M
Total Debt (Recent Filing)$823.88K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 06, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding147,292,860
10 Day Avg. Volume1,051,631
30 Day Avg. Volume2,598,635
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.39
Price to Sales (P/S)1972.04
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue4.58K
Enterprise Value/Gross Profit-18.60
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$8.00Price Target Upside403.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$15.50K
Bulls Say, Bears Say
Bulls Say
Strengthened Cash RunwayA $150M underwritten equity raise materially boosts near-term liquidity, reducing immediate refinancing risk and enabling program execution. This durable cash buffer supports clinical milestones, partnership discussions and planned izicopan development without urgent financing for multiple quarters.
Strategic Focus On IzicopanShifting corporate strategy to prioritize izicopan for ANCA-associated vasculitis and complement-mediated renal diseases concentrates resources on higher-value, specialty indications. A clearer clinical roadmap and targeted Phase 2 planning increase probability of meaningful proof‑of‑concept outcomes and partner interest.
Favorable Preclinical & DDI ProfileLow reactive metabolite formation plus absence of CYP3A4 time-dependent inhibition support a lower safety/interaction risk for chronic use. Durable advantages in safety/DDD profile can ease later-stage development, broaden co‑medication use, and strengthen regulatory and partner positioning.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow demonstrates the business consumes cash to fund R&D and operations. Over the medium term this requires continued external financing or partnerships, raising execution risk and potential dilution if clinical readouts are delayed or inconclusive.
Eroding Equity And AssetsMaterial declines in equity and assets reduce financial cushioning and indicate cumulative losses are depleting capital. Lower balance‑sheet resources limit optionality for parallel programs and heighten sensitivity to adverse trial outcomes or regulatory setbacks over the next several quarters.
Dependence On Equity Financing / Dilution RiskAs a clinical‑stage firm with negligible recurring revenue, InflaRx relies on capital markets and authorized share issuance to fund development. Board powers to expand capital increase dilution risk and can pressure long‑term shareholder returns if future financings remain necessary.
InflaRx News
IFRX FAQ
What was Inflarx N.V.’s price range in the past 12 months?
Inflarx N.V. lowest stock price was $0.74 and its highest was $2.95 in the past 12 months.
What is Inflarx N.V.’s market cap?
Inflarx N.V.’s market cap is $319.63M.
When is Inflarx N.V.’s upcoming earnings report date?
Inflarx N.V.’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Inflarx N.V.’s earnings last quarter?
Inflarx N.V. released its earnings results on May 07, 2026. The company reported -$0.093 earnings per share for the quarter, beating the consensus estimate of -$0.137 by $0.044.
Is Inflarx N.V. overvalued?
According to Wall Street analysts Inflarx N.V.’s price is currently Undervalued.
Does Inflarx N.V. pay dividends?
Inflarx N.V. does not currently pay dividends.
What is Inflarx N.V.’s EPS estimate?
Inflarx N.V.’s EPS estimate is -0.07.
How many shares outstanding does Inflarx N.V. have?
Inflarx N.V. has 147,292,860 shares outstanding.
What happened to Inflarx N.V.’s price movement after its last earnings report?
Inflarx N.V. reported an EPS of -$0.093 in its last earnings report, beating expectations of -$0.137. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of Inflarx N.V.?
Currently, no hedge funds are holding shares in IFRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InflaRx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (403.14% Upside)
$8.00 (403.14% Upside)
Blogger Sentiment
Bullish
IFRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
167.90%
12-Months-Change
Fundamentals
Return on Equity
-94.90%
Trailing 12-Months
Asset Growth
-40.06%
Trailing 12-Months
Company Description
Inflarx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
IFRX Stock 12 Month Forecast
Average Price Target
$8.00
▲(403.14% Upside)
Technical Analysis
Oramed Pharm
―
Atara Biotherapeutics
―
Anixa Biosciences
―
Clene
―
Acumen Pharmaceuticals
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
9.30% Other Institutional Investors
90.67% Public Companies and
Individual Investors